These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26766493)

  • 41. Structural and functional aspects of P-glycoprotein and its inhibitors.
    Mollazadeh S; Sahebkar A; Hadizadeh F; Behravan J; Arabzadeh S
    Life Sci; 2018 Dec; 214():118-123. PubMed ID: 30449449
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of P-glycoprotein in drug resistance in multiple myeloma.
    Abraham J; Salama NN; Azab AK
    Leuk Lymphoma; 2015 Jan; 56(1):26-33. PubMed ID: 24678978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New insights into the P-glycoprotein-mediated effluxes of rhodamines.
    Loetchutinat C; Saengkhae C; Marbeuf-Gueye C; Garnier-Suillerot A
    Eur J Biochem; 2003 Feb; 270(3):476-85. PubMed ID: 12542697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy.
    Bansal T; Jaggi M; Khar RK; Talegaonkar S
    J Pharm Pharm Sci; 2009; 12(1):46-78. PubMed ID: 19470292
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors.
    Yuan S; Wang B; Dai QQ; Zhang XN; Zhang JY; Zuo JH; Liu H; Chen ZS; Li GB; Wang S; Liu HM; Yu B
    J Med Chem; 2021 Oct; 64(19):14895-14911. PubMed ID: 34546748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein.
    Kondratov RV; Komarov PG; Becker Y; Ewenson A; Gudkov AV
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):14078-83. PubMed ID: 11707575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isolated rafts from adriamycin-resistant P388 cells contain functional ATPases and provide an easy test system for P-glycoprotein-related activities.
    Bucher K; Besse CA; Kamau SW; Wunderli-Allenspach H; Krämer SD
    Pharm Res; 2005 Mar; 22(3):449-57. PubMed ID: 15835751
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and Anticancer Activity of A-Ring-Modified Derivatives of Dihydrobetulin.
    Tolmacheva I; Beloglazova Y; Nazarov M; Gagarskikh O; Grishko V
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373011
    [TBL] [Abstract][Full Text] [Related]  

  • 49. P-glycoprotein substrates and antagonists cluster into two distinct groups.
    Scala S; Akhmed N; Rao US; Paull K; Lan LB; Dickstein B; Lee JS; Elgemeie GH; Stein WD; Bates SE
    Mol Pharmacol; 1997 Jun; 51(6):1024-33. PubMed ID: 9187269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs.
    Galmarini CM
    J Exp Ther Oncol; 2002; 2(3):146-52. PubMed ID: 12415630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.
    Zhitomirsky B; Farber H; Assaraf YG
    J Cell Mol Med; 2018 Apr; 22(4):2131-2141. PubMed ID: 29377455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
    J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of anticancer drug-induced P-glycoprotein expression by naringin.
    Ali MM; Agha FG; El-Sammad NM; Hassan SK
    Z Naturforsch C J Biosci; 2009; 64(1-2):109-16. PubMed ID: 19323275
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism.
    Loo TW; Clarke DM
    J Natl Cancer Inst; 2000 Jun; 92(11):898-902. PubMed ID: 10841824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
    Shi Q; Zhang L; Liu M; Zhang X; Zhang X; Xu X; Chen S; Li X; Zhang J
    Biomaterials; 2015 Oct; 67():169-82. PubMed ID: 26218743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
    Jovelet C; Deroussent A; Broutin S; Paci A; Farinotti R; Bidart JM; Gil S
    Eur J Drug Metab Pharmacokinet; 2013 Sep; 38(3):149-57. PubMed ID: 23446814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Substrate Specificity of Aglaia loheri Active Isolate towards P-glycoprotein in Multidrug-Resistant Cancer Cells.
    Dapat E; Jacinto S; Efferth T
    Nat Prod Commun; 2016 Nov; 11(11):1683-1688. PubMed ID: 30475507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs.
    Raghunand N; Martínez-Zaguilán R; Wright SH; Gillies RJ
    Biochem Pharmacol; 1999 May; 57(9):1047-58. PubMed ID: 10796075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Resistance reversal effect of a novel taxane compound NPB304 and its collaboration with verapamil].
    Mei M; Zhang Y; Ren JH; Xie D; Jia YF; Hu JP; Li Y; Dai JG; Chen XG
    Yao Xue Xue Bao; 2014 Sep; 49(9):1279-88. PubMed ID: 25518327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.
    Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E
    Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.